Abstract
Background:
The potential role of bevacizumab in the treatment of ovarian granulosa-cell tumors has not been evaluated.
Case:
An 82 year old woman with refractory ovarian granulosa-cell carcinoma was treated with bevacizumab with symptomatic relief of ascites.
Conclusion:
Bevacizumab may have a role in the management of malignant ascites in the patient with refractory granulosa-cell carcinoma of the ovary which should be confirmed in a larger series of well selected patients.
MeSH terms
-
Aged, 80 and over
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Ascites / drug therapy
-
Bevacizumab
-
Female
-
Granulosa Cell Tumor / drug therapy*
-
Granulosa Cell Tumor / pathology
-
Humans
-
Ovarian Neoplasms / drug therapy*
-
Ovarian Neoplasms / pathology
-
Paclitaxel / administration & dosage
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Bevacizumab
-
Paclitaxel